



BC Centre for Disease Control  
Provincial Health Services Authority

Communicable Diseases and Immunization Service  
655 West 12th Avenue  
Vancouver, BC V5Z 4R4

Tel 604.707.2548  
Fax 604.707.2515  
[www.bccdc.ca](http://www.bccdc.ca)

**Date:** April 26, 2022

**Administrative Circular:** 2022:16

**ATTN:** Medical Health Officers and Branch Offices  
Public Health Nursing Administrators and Assistant Administrators  
Holders of Communicable Disease Control Manuals

**Re: Update to Communicable Disease Control Manual, Chapter 2: Immunization,  
Part 4 – Biological Products**

## **Part 4 – Biological Products**

### **COVID-19 Vaccines**

#### **COVID-19 Vaccine COMIRNATY® (Pfizer-BioNTech) (Adult/Adolescent)**

- **Doses and Schedule:**  
Footnote C has been revised to indicate clients requesting a shorter interval between doses should be informed that this is not optimal for protection, but their request for an earlier dose should be granted, without need for MHO approval.
- The ADDENDUM: Pooling residual vaccine from up to three vials to constitute an extra dose has been removed. While this was an appropriate strategy at the implementation of the COVID-19 vaccination program, vaccine supply is no longer an issue and it is a deviation from best practice.

**Please remove page numbers:** 1-7 dated April 13, 2022  
**Please add new page numbers:** 1-6 dated April 26, 2022

#### **COVID-19 Vaccine COMIRNATY® (Pfizer-BioNTech) (Pediatric)**

- **Doses and Schedule:**  
Footnote C has been revised to indicate clients requesting a shorter interval between doses should be informed that this is not optimal for protection, but their request for an earlier dose should be granted, without need for MHO approval.
- The ADDENDUM: Pooling residual vaccine from up to three vials to constitute an extra dose has been removed. While this was an appropriate strategy at the implementation of the COVID-19 vaccination program, vaccine supply is no longer an issue and it is a deviation from best practice.

**Please remove page numbers:** 1-6 dated March 18, 2022  
**Please add new page numbers:** 1-5 dated April 26, 2022

Page 1 of 3

### **COVID-19 Vaccine SPIKEVAX™ (Moderna)**

- **Doses and Schedule:**

Footnote B has been revised to indicate clients requesting a shorter interval between doses should be informed that this is not optimal for protection, but their request for an earlier dose should be granted, without need for MHO approval.

- The ADDENDUM: Pooling residual vaccine from up to three vials to constitute an extra dose has been removed. While this was an appropriate strategy at the implementation of the COVID-19 vaccination program, vaccine supply is no longer an issue and it is a deviation from best practice.

**Please remove page numbers:** 1-6 dated April 13, 2022

**Please add new page numbers:** 1-5 dated April 26, 2022

### **COVID-19 Vaccine VAXZEVRIA™/COVISHIELD (AstraZeneca/Verity Pharmaceuticals)**

- The ADDENDUM: Pooling residual vaccine from up to three vials to constitute an extra dose has been removed. While this was an appropriate strategy at the implementation of the COVID-19 vaccination program, vaccine supply is no longer an issue and it is a deviation from best practice.

**Please remove page numbers:** 1-5 dated April 13, 2022

**Please add new page numbers:** 1-4 dated April 26, 2022

### **COVID-19 Vaccine (Ad26.COV2.S [recombinant]) (Janssen Inc.)**

- The ADDENDUM: Pooling residual vaccine from up to three vials to constitute an extra dose has been removed. While this was an appropriate strategy at the implementation of the COVID-19 vaccination program, vaccine supply is no longer an issue and it is a deviation from best practice.

**Please remove page numbers:** 1-5 dated April 13, 2022

**Please add new page numbers:** 1-4 dated April 26, 2022

### **COVID-19 Vaccine Nuvaxovid™ (Novavax)**

- **Doses and Schedule:**

Footnote C has been revised to indicate clients requesting a shorter interval between doses should be informed that this is not optimal for protection, but their request for an earlier dose should be granted, without need for MHO approval.

**Please remove page numbers:** 1-3 dated April 13, 2022

**Please add new page numbers:** 1-3 dated April 26, 2022

If you have any questions or concerns, please contact Stephanie Meier, Senior Practice Leader, BCCDC (telephone: 604-707-2577 / email: [stephanie.meier@bccdc.ca](mailto:stephanie.meier@bccdc.ca)).

Sincerely,



Monika Naus MD MHS Sc FRCPC FACPM  
Medical Director  
Communicable Diseases & Immunization Service  
BC Centre for Disease Control

pc:

Provincial Health Officer  
Dr. Bonnie Henry

Dr. Reka Gustafson  
Vice President, Public Health &  
Wellness, PHSA & Deputy Provincial  
Health Officer

Deputy Provincial Health Officer  
Dr. Martin Lavoie

BC Ministry of Health, Population &  
Public Health Division:

Brian Sagar  
Senior Director Communicable  
Disease, Population and Public Health  
Division

Bernard Achampong  
Executive Director,  
Public Health, Planning and Prevention,  
Population and Public Health Division